General Motors Company (GM) Stock Price Today
Aura AI Summary
Key Stats
- $75.80BMarket Cap
- -Volume
- Consumer CyclicalSector
- $90.3052W High
- $55.3552W Low
- -Typical Hold Time
- $178.78BEnterprise Value
- 0.83%Div Yield
- -Trading Activity
Track General Motors Company (GM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, General Motors Company has traded between a low of $55.35 and a high of $90.3, highlighting its annual price range. Buy and sell General Motors Company shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Most Recent News
Airbus leads aerospace market with strong orders despite production challenges
Airbus is outperforming Boeing in commercial aircraft orders, securing 821 net orders in H1 2026 compared to Boeing's 408. Morgan Stanley maintains an "Overweight" rating on Airbus, raising its price target to €255, reflecting confidence in the compa...

Applied Materials stock dips post-earnings despite strong results and raised price target to $700.
Applied Materials reported strong Q3 financial results with revenue up 25% to $9.12 billion and adjusted EPS rising 41% to $3.50, beating Wall Street estimates. However, the stock fell over 5% after earnings due to market expectations being even high...

Ascendis Pharma posts strong Q2 2026 with €339M revenue, boosts price target to $290 by RBC Capital.
Ascendis Pharma reported robust Q2 2026 results with total revenue of €339 million, driven by strong sales of its three main products: YORVIPATH®, SKYTROFA®, and YUVIWEL®. The company achieved a net profit of €207 million and ended the quarter with a...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.